Dulaglutide

Classification

GLP-1 receptor agonist (once-weekly immunoglobulin fusion)

Approval status

Approved medicine

Research status

Labelled indications are defined in product information.

Molecular formula

Insufficient reliable evidence identified.

Molecular weight

Insufficient reliable evidence identified.

Sequence

GLP-1 analogue fused to an IgG4 Fc fragment for weekly dosing.

Primary biological target

Insufficient reliable evidence identified.

Half-life

Insufficient reliable evidence identified.

Routes investigated

Insufficient reliable evidence identified.

Human evidence level

A — Approved clinical use / strong human evidence

A prescription incretin medicine for type 2 diabetes in approved brands. Research-chemical vials labelled dulaglutide are not that product.

GLP-1 receptor agonism: glucose-dependent insulin, glucagon suppression, slowed gastric emptying, reduced appetite.

Glycaemic and GI effects under medical supervision when a licensed product is used.

• Type 2 diabetes
• Cardiovascular outcomes in labelled populations

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: A · Approved clinical use / strong human evidence

Large Phase 3 and outcome programmes exist for licensed dulaglutide, not for anonymous lyophilised vials.

Animal, cell and in-vitro findings are listed separately from human effects.

GLP-1 biology is well mapped; translation depends on the licensed formulation.

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

See the Australian Product Information for the licensed brand. Grey-market vials are not equivalent.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Follow labelled contraindications. Unlicensed research vials are not a substitute.

Approved prescription medicine in multiple jurisdictions as specific branded products.

Cellular Sequence does not sell this as a vial, tablet, oil, or injectable. Educational encyclopaedia listing only.

1. [1] Encyclopaedia note

   Encyclopaedia note